Hormone therapy (HRT)

MHT (menopausal hormone therapy) remains the most effective treatment for significant perimenopause symptoms. At 43, the risk-benefit ratio strongly favours treatment for most women. Everything else in this protocol complements but does not replace a conversation about HRT.

Bioidentical estradiol + micronized progesterone

Mechanism: Transdermal estradiol (patch or gel) delivers 17β-estradiol through the skin, bypassing first-pass liver metabolism. Oral micronized progesterone (Prometrium) protects the uterine lining and has a mild sedative effect that improves sleep. The combination stabilises the hormonal oscillation that drives most symptoms.
Why consider it: Most effective intervention for hot flashes, night sweats, and sleep (70–90% reduction)

Protects bone density during the rapid-loss window

Cardiovascular protection when started within 10 years of menopause onset (the "timing hypothesis")

Cognitive protection — estrogen supports brain glucose metabolism, which declines in peri

Progesterone at bedtime often resolves sleep disruption within days
Evidence: ●●●●● Rock solid — extensive RCT data
The 2022 NAMS Position Statement and 2025 IMS guidelines both designate HRT as first-line for moderate-to-severe vasomotor symptoms. The risks (breast cancer) are lower than previously thought — less than 1% absolute increase for most users, and transdermal estradiol carries essentially no increased VTE risk.
Timeline: Sleep improvement: often within the first week (progesterone effect). Hot flash reduction: 2–4 weeks. Mood stabilisation: 4–8 weeks. Full bone density benefits: 12+ months.

Important

This is a conversation with a qualified menopause specialist, not a DIY decision. The protocol below assumes HRT is being considered in parallel with everything else. If HRT is declined or not appropriate, the supplements, thermal therapy, and lifestyle interventions become even more important.

Perimenopause Protocol